All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Lingang Special Area, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Zhangjiang Hi-Tech Park, all published on March 21, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Zhangjiang Hi-Tech Park
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Lingang Special Area, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Zhangjiang Hi-Tech Park, all published on March 21, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Zhangjiang Hi-Tech Park. Shared-story counts are live from our verified record — not editorial picks.
Shanghai is aggressively implementing a new 'first-class business environment' framework designed to anchor its position as the global epicenter for 'Future Life' industries. The initiative prioritizes regulatory breakthroughs in gene therapy and synthetic biology while expanding the Zhangjiang-Lingang biopharma corridor.